Alteration of Striatal Dopaminergic Neurotransmission in a Mouse Model of DYT11 Myoclonus-Dystonia

Lin Zhang¹, Fumiaki Yokoi¹, Dee S. Parsons², David G. Standaert², Yuqing Li¹*

¹ Department of Neurology, School of Medicine, University of Florida, Gainesville, Florida, United States of America, ² Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Abstract

Background: DYT11 myoclonus-dystonia (M-D) syndrome is a neurological movement disorder characterized by myoclonic jerks and dystonic postures or movement that can be alleviated by alcohol. It is caused by mutations in SGCE encoding ε-sarcoglycan (ε-SG); the mouse homolog of this gene is Sgce. Paternally-inherited Sgce heterozygous knockout (Sgce KO) mice exhibit myoclonus, motor impairment and anxiety- and depression-like behaviors, modeling several clinical symptoms observed in DYT11 M-D patients. The behavioral deficits are accompanied by abnormally high levels of dopamine and its metabolites in the striatum of Sgce KO mice. Neuroimaging studies of DYT11 M-D patients show reduced dopamine D2 receptor (D2R) availability, although the possibility of increased endogenous dopamine, and consequently, competitive D2R occupancy cannot be ruled out.

Methodology/Principal Findings: The protein levels of striatal D2R, dopamine transporter (DAT), and dopamine D1 receptor (D1R) in Sgce KO mice were analyzed by Western blot. The striatal dopamine release after amphetamine injection in Sgce KO mice were analyzed by microdialysis in vivo. The striatal D2R was significantly decreased in Sgce KO mice without altering DAT and D1R. Sgce KO mice also exhibited a significant increase of dopamine release after amphetamine injection in comparison to wild-type (WT) littermates.

Conclusion/Significance: The results suggest ε-SG may have a role in the regulation of D2R expression. The loss of ε-SG results in decreased striatal D2R, and subsequently leads to increased discharge of dopamine which could contribute to the behavioral impairment observed in DYT11 dystonia patients and in Sgce KO mice. The results suggest that reduction of striatal D2R and enhanced striatal dopamine release may contribute to the pathophysiology of DYT11 M-D patients.

Introduction

Dystonia is a neurological disorder characterized by involuntary contractions of both agonist and antagonist muscles of affected body regions that cause twisting and abnormal movements or postures [1]. M-D is a childhood onset movement disorder, clinically characterized by the presence of ‘lighting-like’ myoclonic jerks and dystonic postures or movements that can be alleviated by alcohol [2]. DYT11 M-D patients often show psychiatric abnormalities including alcohol abuse, depression, anxiety, panic attacks, and obsessive-compulsive disorder [3,4,5]. DYT11 M-D is clinically characterized by the presence of ‘lighting-like’ myoclonic jerks and dystonic postures or movement that can be alleviated by alcohol. It is caused by mutations in SGCE encoding ε-sarcoglycan (ε-SG); the mouse homolog of this gene is Sgce. Paternally-inherited Sgce heterozygous knockout (Sgce KO) mice exhibit myoclonus, motor impairment and anxiety- and depression-like behaviors, modeling several clinical symptoms observed in DYT11 M-D patients. The behavioral deficits are accompanied by abnormally high levels of dopamine and its metabolites in the striatum of Sgce KO mice. Neuroimaging studies of DYT11 M-D patients show reduced dopamine D2 receptor (D2R) availability, although the possibility of increased endogenous dopamine, and consequently, competitive D2R occupancy cannot be ruled out.

Methodology/Principal Findings: The protein levels of striatal D2R, dopamine transporter (DAT), and dopamine D1 receptor (D1R) in Sgce KO mice were analyzed by Western blot. The striatal dopamine release after amphetamine injection in Sgce KO mice were analyzed by microdialysis in vivo. The striatal D2R was significantly decreased in Sgce KO mice without altering DAT and D1R. Sgce KO mice also exhibited a significant increase of dopamine release after amphetamine injection in comparison to wild-type (WT) littermates.

Conclusion/Significance: The results suggest ε-SG may have a role in the regulation of D2R expression. The loss of ε-SG results in decreased striatal D2R, and subsequently leads to increased discharge of dopamine which could contribute to the behavioral impairment observed in DYT11 dystonia patients and in Sgce KO mice. The results suggest that reduction of striatal D2R and enhanced striatal dopamine release may contribute to the pathophysiology of DYT11 M-D patients.
membrane fractions, suggests its possible role in the synaptic transmission of the central nervous system [16]. This is supported by recent brain-specific knockout of Sgce in mice. Specific knockout of Sgce in striatum or cerebellar Purkinje cells results in deficits of motor learning, coordination and balance [17,18].

Although the pathophysiological nature of dystonia is largely elusive, basal ganglia, especially striatal dopaminergic system is thought to play a major role. DYT5 dystonia is caused by mutations in either GTP cyclohydrolase gene [19] or tyrosine hydroxylase [20,21]. Mutations in both genes have direct impact on dopamine synthesis. Clinical neuroimaging studies in dystonia patients, including DYT1 dystonia, idiopathic cervical dystonia, and nocturnal myoclonus have showed reduced in vivo striatal D2R binding [22,23,24]. Furthermore, a recent neuroimaging study has revealed reduced striatal D2R binding in DYT11 M-D patients [25]. In addition, a missense mutation (Val154Ile) in a highly conserved region of the D2R was found in one M-D family [2]. D2R-mediated dopaminergic neurotransmission is known to have a key role in the control of movement [26], in reward and reinforcement mechanisms [27], and in psychiatric disorders [20]. Pharmacological agents blocking D2R can result in a dystonic phenotype [29].

We previously reported generation of Sgce KO mice by using Cre-loxP system to flank exon 4 of Sgce and demonstrated that expression of ε-SG is fully abolished in paternally inherited Sgce heterozygous KO mice [9]. The Sgce KO mice exhibit myoclonus, motor impairments, anxiety- and depression-like behaviors [30], which resemble several clinical symptoms observed in DYT11 M-D patients [2]. Moreover, these are accompanied by significantly high levels of dopamine and its metabolites in the striatum [30], implicating abnormal striatal dopaminergic function in Sgce KO mice. In this study, we aim to determine the nature of the dopaminergic dysfunction and found significantly reduced level of striatal D2R with normal level of D1R and DAT in Sgce KO mice. Furthermore, we found increased discharge of striatal dopamine in the mutant mice after amphetamine injection. The results suggest that striatal dopaminergic dysfunction contributes to the pathophysiology of DYT11 M-D.

Results

Increased striatal dopamine release in Sgce KO mice

Previous study has shown increased dopamine and its metabolites in the striatum of Sgce KO mice accompanied with behavioral deficits similar to DYT11 M-D patients [30]. To examine whether the striatal dopaminergic transmission is changed in Sgce KO mice, we used microdialysis to monitor extracellular dopamine levels after amphetamine injection in conscious, freely moving mice as previously described [31]. Amphetamine, a potent psychostimulant, enhances the release of dopamine from pre-synaptic dopaminergic terminals [32]. A single subcutaneous (s.c.) administration of amphetamine (5 mg/kg) induced a remarkable increase of striatal extracellular dopamine level in Sgce KO mice (1,620 ± 45%, n = 6) in comparison to their WT littermates (1,260 ± 118%, n = 8; p < 0.05) 60 minutes after injection (Fig. 1A). Data from each animal were normalized to the corresponding pre-treatment baseline and expressed as a percent of baseline extracellular dopamine level. Repeated ANOVA analysis revealed a significant difference of amphetamine pre-treatment and post-treatment [F (1, 12) = 3.90, p < 0.05]. No significant difference in the basal extracellular dopamine levels was found. Probe locations were verified in all mice at the end of the microdialysis experiment (Fig. 1B).

Decreased striatal D2R without altering D1R and DAT

Neuroimaging studies have revealed decreased in vivo striatal D2R availability in clinical DYT11 M-D patients [25]. In addition, a recent study has reported dopaminergic neuron-specific D2R knockout results in elevated dopamine synthesis and release, hyperactivity and supersensitivity to cocaine [33]. To examine whether loss of ε-SG alters the expression of D2R in the striatum, we analyzed expression level of D2R in Sgce KO and control littermates by Western blot. The D1R, D2R, and DAT levels were standardized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. Striatal D2R was significantly reduced in Sgce KO mice in comparison to control littermates (p < 0.01; Fig. 2A), while striatal D1R and DAT remained unchanged (Fig. 2B, C).

Discussion

Striatal dopamine and their metabolites are increased in Sgce KO mice [30]. To determine the nature of this dopaminergic dysfunction, we used microdialysis to examine the striatal dopamine release in Sgce KO mice. We found significantly increased extracellular dopamine after administration of amphetamine in Sgce KO mouse compared to their WT littermates. Next, to determine if this abnormal release of dopamine in the striatum observed was associated with dysfunction of dopamine receptors or transporter, we used Western blot technique to assess the expression levels of D2R, DAT, and D1R in the striatum and found that D2R was significant decreased without altering D1R and DAT. These results suggest ε-SG may have a role in the regulation of D2R expression. The loss of ε-SG results in decreased striatal D2R, and subsequently leads to increased discharge of dopamine which could contribute to the behavioral impairment observed in Sgce KO mice and DYT11 M-D patients.

Despite of significantly increased striatal dopamine turnover, the level of striatal dopamine is significantly higher in the Sgce KO mice, which indicated a lack of autoreceptor function [30]. Pre-synaptic D2R is present in the soma, dendrites and synaptic terminals of dopaminergic neurons, serving as autoreceptor and providing negative feedback regulation of firing rate [34,35], synthesis and release of dopamine in the terminals [33,36]. Amphetamine is well known to elevate extracellular dopamine levels by reversing DAT and inhibiting dopamine re-uptake through DAT, which results in significantly inducing stimulation-independent non-vesicular dopamine efflux. Dramatic increase of dopamine activates the pre-synaptic D2 receptor and inhibits the activity of dopamine neurons and subsequently inhibits stimulation-dependent exocytosis of dopamine in the terminals [37]. This inhibition appears to be defective in Sgce KO mice (Fig. 1A, 2A).

The D2R results we obtained from Western blot include both post-synaptic D2R on the medium spiny neurons and pre-synaptic D2R on the dopaminergic terminals from substantia nigra. Since majority of striatal D2R are located on the post-synaptic medium spiny neurons, the reduction of striatal D2R may just reflect those in the post-synaptic neurons (Fig. 2A). However, decreased striatal post-synaptic D2R alone will not affect dopamine release from terminals of dopaminergic neurons after amphetamine challenging (Fig. 1A) and result in significantly increased striatal tissue dopamine observed in Sgce KO mice [30]. Furthermore, conditional knockout mice lacking D2 autoreceptor are hyperactive in open field test and show enhanced dopamine release in dorsal striatum and elevated tyrosine hydroxylase activity [33]. Although conditional D2 autoreceptor KO mice exhibit normal motor coordination and no signs of anxiety-like behavior, which differ from the behavioral abnormalities observed in Sgce KO mice.
the differences may be attributed to intact post-synaptic D2R in such D2R conditional KO mice. Alternatively, additional pathways other than D2R may have been disrupted in Sgce KO mice that lead to motor deficits and anxiety-like behaviors. Taken together, it is likely that both pre- and post-synaptic D2R are reduced in the Sgce KO mice.

It is not known how loss of ε-SG led to D2R reduction in the Sgce KO mice. Although the functions of other sarcoglycans are well documented, the functions of ε- and ζ-sarcoglycans, which express widely in central nervous system, are less clear. Sarcoglycan family is well known for its major role in stabilizing membrane through forming complex with dystroglycan and dystrophin during the muscle contraction. Mutations in α, β, γ, and δ-sarcoglycan result in autosomal recessive limb-girdle muscular dystrophies (LGMD) [13]. mRNA for ε-SG is expressed at high level in dopaminergic neurons [15], suggesting that it may have an important role in stabilizing the membrane of dopaminergic neurons. Indeed, our results show that elimination of ε-SG resulted in the reduction of D2R in the striatum (Fig. 2A). We previously reported brain-specific alternatively spliced mRNA variants of ε-SG in mice. These two variants possess unique C-terminal sequences which are similar to PDZ-binding motifs [9]. Many G-protein coupled receptors contain a PDZ binding motif at their C-terminals enabling other PDZ proteins to associate and scaffold multi-protein complexes that can modulate receptor properties such as trafficking, signaling, receptor stability and cell distribution [38]. Whether ε-SG acts in a similar fashion to modulate D2R remains to be investigated in the future studies.

Western blot analysis showed a selective reduction of striatal D2R without altering mRNA level of striatal D2R (Fig. 2 and Fig. S1). It is not known how loss of ε-SG specifically affects D2R alone. Amphetamine and its derivatives release dopamine from dopaminergic terminals and cause excessively increased level of extracellular dopamine [32]. Addictive drug is thought to “hijack” normal natural rewards system, such as food or sexual activity, by quickly elevating the level of extracellular dopamine to exert their reinforcing properties. Upon dopamine stimulation, agonist-activated D1R and D2R are rapidly silenced by undergoing endocytosis followed by trafficking to early endosomes. D1R is recycled back to the plasma membrane after desensitization, while D2R is targeted by interaction with GPCR-associated sorting protein and degraded in lysosomes [39]. ε-SG located on the cell membrane may have important roles in regulating endocytic degradation of D2R.

In conclusion, we found significant and selective reduction of striatal D2R in Sgce KO mice that is consistent with the
Became targets of endocytic desensitization process. Subsequently increased ligand occupied D2 receptors which enhanced dopamine synthesis in terminals [30] and increased of D2 autoreceptor in dopaminergic neurons may result in neuroimaging results in clinical DYT11 M-D patients [25]. Lack of D2 autoreceptor in dopaminergic neurons may result in enhanced dopamine synthesis in terminals [30] and increased dopamine release after amphetamine injection in the striatum (Fig. 1A). These results support the idea that basal ganglia play very important role in manifesting of dystonia, and suggest that loss of ε-SG may influence the homeostasis of D2R.

Limitations
The reduction of striatal D2 receptor (Figure 2A) reflects the combination of pre-synaptic and post-synaptic D2 receptors. Although Western blotting result showed the expression level of striatal DAT is not altered and microdialysis experiment showed that extracellular level of dopamine returned to basal level after stimulation, however the alteration of DAT functions cannot be completely ruled out. There is alternative explanation of obtained results that is due to unknown mechanisms underlying enhanced striatal dopamine release from loss of ε-SG protein, and subsequently increased ligand occupied D2 receptors which became targets of endocytic desensitization process.

Materials and Methods

Animals
All experiments were carried out in compliance with the USPHS Guide for Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at the University of Alabama at Birmingham with Animal Protocol Number 10008918. Sgear heterozygous KO male mice were crossed with C57BL/6 female mice to obtain paternally-inherited Sgear heterozygous KO (Sgear KO) mice and WT littermates as previously described [9]. Genotyping for Sgear KO mice and WT littermates was performed by multiplex PCR using SgearF (5′-CTGTAAACAACACACTGAGTAC-3′) and SgearED (5′-AC-AGCTTTGAACTACCTTTGTGCA-3′) primers for the deleted exon 4 locus [9] and DAT-Up (5′-TCCATAGCCAAATCTCCTCAGTC-3′) and DAT-Lwt (5′-TTGATGGGAGGTTGGATTTGGTC-3′) primer sets for dopamine transporter gene as an internal control [17]. Mice were housed under a 12-h-light/dark cycle with free access to food and water. All experiments were performed by investigators blind to the genotypes and the animals were decoded after all experiments were finished.

Drugs administration
Amphetamine (5 mg/kg; Sigma-Aldrich Corporation, St Louis, MO) was dissolved in physiological saline and was injected subcutaneously in a volume of 10 ml/kg, as previously described [40].

In vivo microdialysis
Five-month-old Sgear KO mice (n = 6) and their WT littermates (n = 8) were used in microdialysis study, procedure was performed in alert, freely moving mice as previously described [31]. Briefly, mice were anesthetized with ketamine/xylose (100/10 mg/kg) before the stereotaxic implantation of a probe (Eicom; P-I-6-02) into the striatum at coordinates (+0.0 mm anteroposterior, +2.5 mm mediolateral from the bregma, and −4.4 mm dorsoventral with respect to dura). Probes were secured onto the skull using stainless-steel screws and dental acrylic. Twenty-four hours after surgery, in vivo microdialysis was performed on conscious mice. Probe was perfused continuously with artificial CSF (147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl2) at a flow rate of 1.5 μl/min. The dialysate was collected in 20-min fractions. Six samples were obtained in order to establish the baseline levels of extracellular dopamine prior to the administration of amphetamine. Dopamine level of microdialysis samples were measured by high-performance liquid chromatography (HPLC) using a reversed phase column (Dionex ESA MD-150×3.2 150 mm Dionex, Chelmsford, MA, USA), as previously described [41]. Probe locations were verified in all mice at the end of the microdialysis experiment. The animal was anesthetized with ketamine/xylose (100/10 mg/kg) and perfused transcardially with 4% paraformaldehyde in saline and brains were removed and placed in fixative overnight at 4°C. After equilibrated in 30% sucrose in 0.1 M phosphate buffer, the brains were sectioned. Coronal sections were cut at 50 μm thickness using a sliding microtome (Histoslide 2000, Reichert-Jung). The sections were Nissl stained.

Western blot analysis
Striatum was dissected from brains of 5-month-old Sgear KO mice (n = 4) and WT littermates (n = 3). The tissue was homogenized in 200 μl of ice-cold lysis buffer contained 50 mM Tris-Cl (pH 7.4), 175 mM NaCl, 5 mM EDTA with a protease inhibitor cocktail tablet (Roche) and followed by sonication for 10 sec. Triton X-100 was added to 1% w/v final concentration and the mixture was incubated on ice for 30 min and centrifuged at 10,000×g for 15 min at 4°C as described earlier [8]. The protein concentration was measured by the Bradford assay with bovine serum albumin (BSA; Fisher Scientific) as standards. The homogenates were mixed with the SDS-PAGE loading buffer and boiled for 5 min, incubated on ice for 1 min, and then centrifuged...
for 5 min to obtain the supernatant. Of the samples, 30 μg was loaded on a 10% SDS-PAGE and the separated proteins were transferred to the PVDF membrane. After blocking with 5% BSA or 5% non-fat milk (Bio-Rad), TBS-T buffer contained 20 mM Tris-Cl (pH 7.6), 137 mM NaCl, 0.1% Tween 20, the membranes were incubated overnight at 4°C with rabbit anti-dopamine D2 receptor (Millipore, AB5084P) at 1:500 dilution in 5% BSA TBS-T buffer, goat anti-dopamine D1 receptor (Santa Cruz, sc-31478) at 1:200 dilution and rabbit anti-dopamine transporter (Millipore, AB1591P) at 1:500 dilution in 5% non-fat milk TBS-T buffer. Membranes were washed for three times and then incubated with bovine anti-rabbit IgG-HRP (Santa Cruz, sc-2370) or donkey anti-goat IgG-HRP (Santa Cruz, sc-2026) in the 5% non-fat milk TBS-T at room temperature for 1 hour. GAPDH was used as a loading control, and probed with HRP-conjugated GAPDH antibody (Santa Cruz, sc-25778). The band was detected by using Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, Santa Cruz, sc-25778). The signals were captured by Alpha Innotech FluorChem FC2 and quantified with UN-SCAN-IT gel (Silk Scientific) software. Each Western blot experiment was repeated three times.

RNA preparation and RT-PCR analysis

Striatum was dissected from brains of 4-month-old Sge KO mice (n = 2) and WT littermates (n = 2). RNA was extracted from striatum by using RNeasy Fibrous Tissue Mini Kits (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol; cDNA was generated from 1 μg of total RNA using random primers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). PCR was performed using the cDNA as template with the following primer sets: forward D2S (5'-CACCACCTCAGATGCTGGCAG-3'), and reverse D2E8 (5'-TTTGCTATGTAGCCGTGGTTGGATG-3') for dopamine receptor D2S; forward D2E7 (5'-GGAGTCTCCAGGTAA-CAGGCGG-3'), and reverse D2E8 for dopamine receptor D2L (42); forward E1 (5'-CACCCGCGGACACAGCTTTTGG-3'), and reverse E2 (5'-AATACGCGGCGAGCATGTCG-3') for β-actin. PCR products were separated by 2% agarose gel electrophoresis and visualized by ethidium bromide staining [43].

Statistical analysis

The data are presented as the mean ± standard error of the mean (SEM). The calculation was carried out using the STATVIEW 5.0J software (STATVIEW 5.0J, Tokyo, Japan). The data from the microdialysis were analyzed by repeated ANOVA, comparisons of WT and KO groups were analyzed using student’s t-test. The data of the Western blot were analyzed by One-way ANOVA. For all analyses, a p-value less than 0.05 was considered statistically significant (*p<0.05, **p<0.01).

Supporting Information

Figure S1 RT-PCR analysis of striatal D2R. Semiquantitative RT-PCR analysis of RNA samples extracted from striatum of sge KO and their WT littermates, β-actin was used as control in this test. The quantified results are shown in the right side. The vertical bars represent means ± SEM of 2 pairs of mice. (EPS)

Acknowledgments

We thank Kevin Feng and the staff for animal care, Alena Samal and Miki Jimno for their technical assistance, and Dr. Yuan-Hu Jin for discussion and suggestion.

Author Contributions

Conceived and designed the experiments: LZ DGS YL. Performed the experiments: LZ. Analyzed the data: LZ. Contributed reagents/materials/analysis tools: LZ FY DSP DGS YL. Wrote the paper: LZ DGS YL.

References

1. Fahn S (1988) Concept and classification of dystonia. Adv Neurol 50: 1–8.
2. Klein C, Brin MF, Kramer MR, Sema-Estèves M, de Leon D, et al. (1999) Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A 96: 5173–5176.
3. Zimprich A, Grabowski M, Amusia F, Naumann M, Berg D, et al. (2001) Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29: 66–69.
4. Doheny DO, Brin MF, Morrison GE, Smith CJ, Walker RH, et al. (2002) Phenotypic features of myoclonus-dystonia in three kindreds. Neurology 59: 1187–1196.
5. Mishulholin A, Placeck M, Lemnou G, Taanman JW, Warner TT (2007) Myoclonus-dystonia syndrome with severe depression is caused by an exon-skipping mutation in the epsilon-sarcoglycan gene. Mov Disord 22: 1173–1175.
6. Grabowski M, Zimprich A, Lorenz-Depiereux B, Kalscheuer V, Asmus F, et al. (2007) The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 15: 123–130.
7. Piras G, El Khoury A, Koelov S, Escalante-Alcalde D, Hernandez L, et al. (2000) ZAC1 (Zell), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. Mol Cell Biol 20: 3300–3315.
8. Yokoi F, Yang G, Li J, DeAndrade MP, Zhou T, et al. (2010) Earlier onset of motor deficits in mice with double mutations in Dyt1 and Sge. J Neurochem 140: 459–466.
9. Yokoi F, Deng MT, Mitsui S, Li Y (2005) Exclusive paternal expression and novel alternatively spliced variants of epsilon-sarcoglycan mRNA in mouse brain. FEBS Lett 579: 4822–4828.
10. Ritz K, van Schaik BD, Jakobs ME, van Kampen AH, Arounia E, et al. (2011) SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis? Eur J Hum Genet 19: 132–137.
11. Tezenas du Montcel S, Clot F, Viallard-Meire E, Liaudet P, et al. (2006) Episodic sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet 43: 394–400.
12. Esapa CT, Waite A, Locke M, Benson MA, Kraus M, et al. (2007) SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 16: 327–342.
13. Otowa E, Mizuno Y, Hagisawa Y, Sasaki T, Yoshida M (2005) Molecular cell biology of the sarcoglycan complex. Muscle Nerve 32: 563–576.
14. Xiao J, LeDoux MS (2003) Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan. Brain Res Mol Brain Res 119: 123–143.
15. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, et al. (2005) Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol 482: 50–73.
16. Nishiyama A, Endo T, Takeda S, Imamura M (2004) Identification and characterization of epsilon-sarcoglycan in the central nervous system. Brain Res Mol Brain Res 125: 701–706.
17. Yokoi F, Deng MT, Zhou T, Li Y (2012) Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models. Hum Mol Genet 21: 916–925.
18. Yokoi F, Deng MT, Yang G, Li J, Dordochi A, et al. (2012) Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models. Behav Brain Res 227: 12–20.
19. Ichimori H, Ohye T, Takahashi E, Seki N, Hori T, et al. (1994) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8: 236–242.
20. Knappskog PM, Flarnmark T, Mallet J, Ludecke B, Bartholome K (1995) Recessionally inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 4: 1209–1212.
21. Ludecke B, Bartholome K (1995) Frequent sequence variant in the human tyrosine hydroxylase gene. Hum Genet 95: 716.
22. Asamura K, Ku Y, Okahchi J, Dhawan V, Chaly T, et al. (2005) Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 64: 347–349.
23. Naumann M, Parker RW, Reiners K, Lange KW, Becker G, et al. (1998) Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 13: 319–323.
24. Staedt J, Stoppel G, Koehler A, Riemann H, Hajak G, et al. (1995) Nocturnal dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 10: 459–466.
25. Stoodley R, Stoppa G, Koehler A, Riemann H, Hajak G, et al. (1995) Nocturnal myoclonus syndrome (periodic movements in deep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 245: 55–60.
25. Beukers RJ, Booij J, Weinscher N, Zijlstra F, van Amelsvoort TA, et al. (2009) Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging 36: 269–274.

26. Wang Y, Xu R, Sasaki T, Tonegawa S, Kung MP, et al. (2000) Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 20: 8309–8314.

27. Musale G, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189–225.

28. Arimianni T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6: 577–582.

29. Skidmore F, Reich SG (2005) Tardive Dystonia. Curr Treat Options Neurol 7: 231–236.

30. Yokoi F, Dang MT, Li J, Li Y (2006) Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem 140: 141–146.

31. Zhang L, Shirayama Y, Iyo M, Hashimoto K (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32: 2004–2010.

32. Sulzer D (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69: 628–649.

33. Bello EP, Mateo Y, Gelman DM, Noain D, Shin JH, et al. (2011) Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat Neurosci 14: 1033–1038.

34. Ford CP, Gantz SC, Phillips PE, Williams JT (2010) Control of extracellular dopamine at dendrite and axon terminals. J Neurosci 30: 6975–6983.

35. Paladini CA, Robinson S, Morikawa H, Williams JT, Palminteri RD (2003) Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism. Proc Natl Acad Sci U S A 100: 2866–2871.

36. Wolf ME, Roth RH (1990) Autoreceptor regulation of dopamine synthesis. Annu N Y Acad Sci 604: 323–343.

37. Schmitz Y, Benoit-Marand M, Gouon F, Sulzer D (2003) Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87: 273–289.

38. Magalhaes AC, Dumn H, Ferguson SS (2011) Regulation of G Protein-Coupled Receptor Activity, Trafficking and Localization by Gpcr-Interacting Proteins. Br J Pharmacol.

39. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladfelter F, et al. (2005) Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci U S A 102: 11321–11326.

40. Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, et al. (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 30: 1391–1395.

41. Bicigo A, Kim MO, Sharma N, Cha JH, Bresakfield XO, et al. (2007) Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 102: 783–788.

42. Dang MT, Yokoi F, Cheetham CC, Lu J, Vo V, et al. (2012) An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 DeltaGAG knock-in mice. Behav Brain Res 226: 463–472.

43. Zhang L, Haraguchi S, Koda T, Hashimoto K, Nakagawara A (2011) Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice. J Biomed Biotechnol 2011: 831092.